Bhat Suneel B, Liss Frederic E, Beredjiklian Pedro K
Research performed at Rothman Institute, Philadelphia, Pennsylvania, USA.
Rothman Institute Department of Orthopaedics, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Arch Bone Jt Surg. 2018 Sep;6(5):371-375.
There are a number of different implant choices for surgical treatment of distal radius fractures, often determined by surgeon preference or availability. Although no one volar plate demonstrates superior outcomes, there are significant cost differences absorbed by hospitals and surgical centers. This purpose of this study is to characterize the economic implications of implant selection in the surgical management of distal radius fractures.
A retrospective review of billing records at a mid-size community surgicenter was conducted for CPT codes 25607, 25608, and 25609 between 1/1/2014 and 6/1/2014, and associated implant costs and facility reimbursements were collected. A unique stochastic simulation model was developed from derived probabilities, reimbursements, and costs, and analyzed by Monte Carlo simulation.
Reimbursement to the facility for distal radius ORIF cases ranged from $1,102.20 to $7,393.86, with an average of $3,824.56. Per case operating costs to the facility ranged from $1,250 to $7,270, with an average of $2,817.42. In the US, variations in implant cost 25% above or below the mean translates to annual operating profits realized by facilities ranging from a loss of $57,047,720 to profits of $55,189,729. On average, per case operating costs for distal radius fractures need to be less than $2956 for facilities to realize a per case profit.
Value based purchasing is by necessity becoming integrated into clinical decision making by orthopaedic surgeons. Variations of 25% around the mean per case operating cost can vary facility operating margins by $112,237,450 annually. Arming the orthopaedic surgeon with the realities of the cost of implant selection in the operative management of distal radius fractures will lead to better value based decision making, substantial cost savings to the US hospital system, and ultimately payers and patients.
桡骨远端骨折的手术治疗有多种不同的植入物选择,通常由外科医生的偏好或可获得性决定。虽然没有一种掌侧钢板显示出更好的疗效,但医院和手术中心承担的成本存在显著差异。本研究的目的是描述桡骨远端骨折手术治疗中植入物选择的经济影响。
对一家中型社区手术中心2014年1月1日至2014年6月1日期间的CPT编码25607、25608和25609的计费记录进行回顾性研究,并收集相关的植入物成本和机构报销费用。根据推导的概率、报销费用和成本建立了一个独特的随机模拟模型,并通过蒙特卡洛模拟进行分析。
桡骨远端切开复位内固定术病例的机构报销费用从1102.20美元到7393.86美元不等,平均为3824.56美元。机构每例手术成本从1250美元到7270美元不等,平均为2817.42美元。在美国,植入物成本比平均水平高25%或低25%的变化会导致机构实现的年度运营利润从亏损57047720美元到盈利55189729美元不等。平均而言,桡骨远端骨折每例手术成本需要低于2956美元,机构才能实现每例盈利。
基于价值的采购必然会融入骨科医生的临床决策中。每例手术成本围绕平均值上下25%的变化每年可使机构运营利润率相差112237450美元。让骨科医生了解桡骨远端骨折手术治疗中植入物选择成本的实际情况,将有助于做出更好的基于价值的决策,为美国医院系统、最终为付款人和患者节省大量成本。